Only Available By Prescription
Sign up to get notified if we do in the future.
We guarantee the lowest price on all of our prescription products. If you find your medications cheaper at any other recognized licensed mail order pharmacy, we will not only match their price, we will beat it by 25% of the difference. It is our 125% price match guarantee!
Example: If you find a product on Canada Drugs Direct for $50.00 and find the same product for $40.00 at another mail order pharmacy, we will provide you with a $12.50 discount, bringing your total to $37.50.
To get the discount please make sure to mention the price match to the customer service team when they call to collect payment for your order. Or call toll free at 1-888-904-8467 to place the order through the phone.
Terms & Conditions of Program
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Aldurazyme (laronidase) is a recombinant form of human a-L-iduronidase, an enzyme deficient in patients with mucopolysaccharidosis I (MPS I), including Hurler, Hurler-Scheie, and Scheie syndromes. It is indicated for the treatment of non-neurological manifestations of MPS I. Laronidase is designed to replace the deficient endogenous enzyme and reduce the accumulation of glycosaminoglycans (GAGs) in tissues, thereby improving pulmonary function, mobility, and reducing hepatomegaly. Due to limited blood–brain barrier penetration, Aldurazyme is not effective for central nervous system (CNS) symptoms of MPS I.
| Fact Table | |
| Formula | C5974H9093N1567O1742S34 |
| License | US FDA, EMA |
| Bioavailability | Not applicable (IV only) |
| Legal status | Prescription only (Rx-only) |
| Chemical Name | Laronidase |
| Elimination half-life | 1.5 to 3.6 hours |
| Dosage (Strength) | 0.58 mg/mL solution; 0.58 mg/kg once weekly (IV infusion) |
| Pregnancy | Consult a doctor (Category B) |
| Brands | Aldurazyme |
| Protein binding | Not applicable (recombinant enzyme) |
| PubChem CID | 16132254 |
| MedlinePlus | a604043 |
| ChEBI | 139014 |
| ATC code | A16AB05 |
| DrugBank | DB00090 |
| KEGG | D04717 |
| Routes of administration | Intravenous (IV) |
Aldurazyme is administered as a once-weekly intravenous infusion at a recommended dose of 0.58 mg/kg. The infusion should be administered over approximately 3 to 4 hours and may require premedication with antihistamines and/or antipyretics to minimize the risk of infusion-associated reactions. Initial infusions should be given in a clinical setting equipped to manage anaphylaxis and other acute hypersensitivity reactions. Dosage adjustments are not routinely required based on age, but clinical monitoring is essential throughout therapy.
Each vial of Aldurazyme contains 2.9 mg of laronidase in 5 mL of solution (0.58 mg/mL). Inactive ingredients include sodium chloride, sodium phosphate monobasic monohydrate, sodium phosphate dibasic heptahydrate, and polysorbate 80 in water for injection. The solution is preservative-free and requires dilution prior to infusion.
Aldurazyme is contraindicated in patients with known life-threatening hypersensitivity to laronidase or any of the excipients. Use is also contraindicated during acute respiratory illness due to the risk of severe infusion-related reactions.
Infusion-associated reactions (IARs), including severe anaphylaxis, have been reported. Patients with compromised respiratory function or preexisting airway disease should be closely monitored during infusions. Pretreatment with antihistamines, antipyretics, or corticosteroids may be necessary, particularly in patients with prior reactions. Anaphylaxis can occur at any time during treatment and may necessitate immediate discontinuation. Long-term immune response, including the development of IgG antibodies to laronidase, may impact efficacy or safety. Use in pediatric populations has demonstrated benefit in delaying progression of somatic symptoms, though early initiation is critical to optimize outcomes.
Common and serious side effects associated with Aldurazyme include:
Exceptional Customer Service
We pride ourselves on delivering excellent customer service with as much accessibility as possible.
If you have any questions at all, or would like to place an order, you are encouraged to contact us by toll-free
phone 1-888-904-8467 or email info@canadadrugsdirect.com.
Top Safety and Quality
Canada Drugs Direct employs dedicated, professional licensed pharmacists to ensure that each and every order is reviewed before it is dispensed for the safety and health of our customers. At CanadaDrugsDirect.com, your health is our top priority.
Product Reviews